» Articles » PMID: 21457210

Evaluation of Epidermal Nerve Density and Opioid Receptor Levels in Psoriatic Itch

Overview
Journal Br J Dermatol
Specialty Dermatology
Date 2011 Apr 5
PMID 21457210
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Psoriasis is a complex, multifactorial inflammatory skin disease with genetic and environmental interactions. Patients with psoriasis exhibit erythematous plaques with itch, but the mechanisms of psoriatic itch are poorly understood.

Objectives: This study was performed to investigate epidermal nerve density and opioid receptor levels in psoriatic skin with or without itch.

Methods: Twenty-four patients with psoriasis aged between 39 and 82 years were included in this study. The number of epidermal nerve fibres, the levels of semaphorin 3A (Sema3A) and the expression patterns of μ- and κ-opioid systems were examined immunohistologically in skin biopsies from psoriatic patients with or without itch and healthy volunteers as controls.

Results: The number of epidermal nerve fibres tended to increase in approximately 40% of psoriatic patients with itch compared with healthy controls, while such intraepidermal nerves were not observed in other itchy patients. In comparison with healthy controls, Sema3A levels also tended to decrease in the epidermis of psoriatic patients with itch. However, no relationship was found between nerve density and Sema3A levels in the epidermis of psoriatic patients with itch. The levels of μ-opioid receptor and β-endorphin in the epidermis were the same in healthy controls and psoriatic patients with or without itch. The levels of κ-opioid receptor and dynorphin A were significantly decreased in the epidermis of psoriatic patients with itch compared with healthy controls.

Conclusions: Based on Sema3A levels in the epidermis, epidermal opioid systems, rather than hyperinnervation, may be involved in the pathogenesis of psoriatic itch.

Citing Articles

Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study.

Renkhold L, Pereira M, Loser K, Metze D, Baeumer D, Melzer N Acta Derm Venereol. 2024; 104:adv40737.

PMID: 39565228 PMC: 11600607. DOI: 10.2340/actadv.v104.40737.


Botulinum toxin injection shows promise in nail psoriasis: A comparative randomized controlled trial.

Juntongjin P, Srisinlapakig S, Nitayavardhana S JAAD Int. 2024; 16:105-111.

PMID: 38873171 PMC: 11170438. DOI: 10.1016/j.jdin.2024.03.021.


The Involvement of Semaphorins in the Pathogenesis of Skin Diseases.

Sluczanowska-Glabowska S, Jankowska O, Staniszewska M, Pawlik A Int J Mol Sci. 2023; 24(24).

PMID: 38139064 PMC: 10743238. DOI: 10.3390/ijms242417235.


Pathomechanism of Pruritus in Psoriasis and Atopic Dermatitis: Novel Approaches, Similarities and Differences.

Kaczmarska A, Kwiatkowska D, Skrzypek K, Kowalewski Z, Jaworecka K, Reich A Int J Mol Sci. 2023; 24(19).

PMID: 37834183 PMC: 10573181. DOI: 10.3390/ijms241914734.


Endogenous Opioid Imbalance as a Potential Factor Involved in the Pathogenesis of Chronic Kidney Disease-Associated Pruritus in Dialysis Patients.

Wala-Zielinska K, Swierczynska-Mroz K, Krajewski P, Nowicka-Suszko D, Krajewska M, Szepietowski J J Clin Med. 2023; 12(7).

PMID: 37048558 PMC: 10094828. DOI: 10.3390/jcm12072474.